Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 3,604 | — | 3,604 | — |
| Operating expenses: | ||||
| Cost of goods sold | 93 | — | 93 | — |
| Research and development | 97,019 | 102,696 | 200,865 | 218,923 |
| Selling, general and administrative | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | 750 | — | 750 | — |
| Total operating expenses | 134,145 | 134,963 | 271,502 | 280,543 |
| Loss from operations | (130,541) | (134,963) | (267,898) | (280,543) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s R&D?
- Denali Therapeutics Inc. (DNLI) reported R&D of $97.02M in Q2 2026.
- How has Denali Therapeutics Inc.'s R&D changed year-over-year?
- Denali Therapeutics Inc.'s R&D decreased by 5.5% year-over-year, from $102.7M to $97.02M.
- What is the long-term trend for Denali Therapeutics Inc.'s R&D?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s R&D has grown at a 12.1% compound annual growth rate (CAGR), from $265.35M to $418.78M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Denali Therapeutics Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude